4 Promising Drug Developments in Psoriatic Arthritis Treatment Market According to the latest data from the National Psoriasis Foundation, over 8 million people in the United States have psoriasis. In psoriatic arthritis, the underlying inflammation affects bodily systems like the lungs, heart, and eyes. One primary goal in treating psoriatic arthritis or psoriasis is achieving skin clearance. As per Inkwood Research, the global psoriatic arthritis treatment market growth is anticipated to progress at a CAGR of 7.64% during 2023-2032. This blog discusses the four promising drug developments for psoriatic arthritis treatment. 1. Sun Pharma announces China NMPA Approval for ILUMETRI On 30th May 2023, Sun Pharmaceutical Industries announced the approval of a New Drug Application (NDA) for tildrakizumab injection under ILUMETRI by the National Medical Products Administration of the People's Republic of China. ILUMETRI is indicated for treating adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In June 2019, tildrakizumab was out-licensed by a China Medical System Holdings Limited (CMS) subsidiary for commercialization, regulatory filings, and development of the product in Greater China. As per CMS, the Phase III clinical trial results showed a continual increase in the primary efficacy assessment indicator PASI 75 response over the treatment time. Tildrakizumab Injection has also been approved in the United Kingdom, the United States, Japan, European Union, Hong Kong, Australia, Canada, Switzerland, etc., under brands like ILUMETRI and ILUMYA. 2. BIOCAD showcases Netakimab's efficacy at EULAR 2020 Netakimab is an anti-interleukin 17A antibody approved and humanized for treating moderate-tosevere plaque psoriasis. The phase III clinical trial PATERA assessed the Netakimab's effects on the symptoms and signs of psoriatic arthritis, including quality of life, skin manifestation, and disease activity. The trial included 194 eligible psoriatic arthritis patients who received either a placebo or 120 mg of Netakimab subcutaneously for 24 weeks. The drug was well-endured and the effects were mild to moderate. No anti-drug antibodies were detected and no treatment-related severe adverse effects. 3. Priovant Therapeutics' Brepocitinib on a Unique Quest Brepocitinib is a drug being tested for possible treatment for many immunocompromising conditions like dermatomyositis, ulcerative colitis, and systemic lupus erythematosus. However, Brepocitinib's phase II trial has also exhibited positive outcomes for psoriatic arthritis treatment. Further, Brepocitinib works by hindering the inflammation-causing immune response, which forms the core of psoriatic arthritis. The drug is unique since it obstructs two enzymes, JAK1 and TYK2, which play a huge role in autoimmune disease. Presently, Brepocitinib is the only dual inhibitor in late-stage development. Dr. Ruth Ann Vleugels, a principal investigator for the Priovant study of Brepocitinib in dermatomyositis, says, "Years of experience using JAK inhibitors in patients with dermatomyositis
has shown us that these agents can profoundly benefit patients with uncontrolled disease. Given the devastating manifestations of dermatomyositis and its substantial impact on quality of life, the benefits of treatment with JAK inhibitors outweigh the potential risks in the vast majority of patients in our clinic." (Source) 4. AbbVie gets FDA approval for SKYRIZI® (risankizumab-rzaa) On 21st January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) 's approval of SKYRIZI® for treating adults with active psoriatic arthritis. The approval is supplemented by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2. These studies assessed SKYRIZI®'s safety and efficacy in adults with active psoriatic arthritis. SKYRIZI dictates a dosing procedure for psoriatic arthritis, which is in tandem with the existing procedure for moderate-to-severe plaque psoriasis patients. It displayed considerable improvements across many manifestations of psoriatic arthritis, including painful, tender, and swollen joints. Says Alan J. Kivitz, M.D, clinical trial investigator of KEEPsAKE, "In the pivotal KEEPsAKE trials, SKYRIZI demonstrated improvements across a number of psoriatic arthritis symptoms, including joint pain, enthesitis and dactylitis. This approval provides both dermatologists and rheumatologists with an option that helps improve skin and joint symptoms in patients with active psoriatic arthritis, alongside a quarterly dosing schedule that may fit their patients' lifestyle." (Source) Such product developments enhance the global psoriatic arthritis treatment market growth prospects. FAQs:
Which is the largest revenue-generating region in the global psoriatic arthritis treatment market? A: North America is the largest revenue-generating region in the global psoriatic arthritis treatment market. Which is the prominent drug type in the global psoriatic arthritis treatment market? A: Disease-modifying antirheumatic drugs (DMARDs) are the prominent drug type in the global psoriatic arthritis treatment market.